

Robert Daniel Beauchamp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6437314/publications.pdf>

Version: 2024-02-01

96
papers

8,496
citations

36271

51
h-index

42364

92
g-index

96
all docs

96
docs citations

96
times ranked

9062
citing authors

#	ARTICLE	IF	CITATIONS
1	Colon epithelial cell TGF β 2 signaling modulates the expression of tight junction proteins and barrier function in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G936-G957.	1.6	23
2	Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. <i>Gastroenterology</i> , 2019, 156, 662-675.e7.	0.6	56
3	Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. <i>Histopathology</i> , 2016, 68, 183-190.	1.6	23
4	Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. <i>Oncogene</i> , 2015, 34, 4570-4580.	2.6	75
5	Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. <i>Oncotarget</i> , 2015, 6, 22934-22948.	0.8	11
6	Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. <i>Gut</i> , 2014, 63, 622-634.	6.1	163
7	Nuclear Factor of Activated T-cell Activity Is Associated with Metastatic Capacity in Colon Cancer. <i>Cancer Research</i> , 2014, 74, 6947-6957.	0.4	96
8	Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. <i>Laboratory Investigation</i> , 2014, 94, 409-421.	1.7	58
9	Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome. <i>Cancer Research</i> , 2013, 73, 2955-2964.	0.4	34
10	Four Jointed Box 1 Promotes Angiogenesis and Is Associated with Poor Patient Survival in Colorectal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e69660.	1.1	27
11	Deciphering Genomic Alterations in Colorectal Cancer through Transcriptional Subtype-Based Network Analysis. <i>PLoS ONE</i> , 2013, 8, e79282.	1.1	15
12	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. <i>Gut</i> , 2012, 61, 1291-1298.	6.1	74
13	XIAP Monoubiquitylates Groucho/TLE to Promote Canonical Wnt Signaling. <i>Molecular Cell</i> , 2012, 45, 619-628.	4.5	72
14	A Network-Based Gene Expression Signature Informs Prognosis and Treatment for Colorectal Cancer Patients. <i>PLoS ONE</i> , 2012, 7, e41292.	1.1	35
15	Kaiso Directs the Transcriptional Corepressor MTG16 to the Kaiso Binding Site in Target Promoters. <i>PLoS ONE</i> , 2012, 7, e51205.	1.1	22
16	Identification and Optimization of Small Molecules That Restore E-Cadherin Expression and Reduce Invasion in Colorectal Carcinoma Cells. <i>ACS Chemical Biology</i> , 2011, 6, 452-465.	1.6	35
17	Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. <i>Oncogene</i> , 2011, 30, 3234-3247.	2.6	133
18	BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 4056-4069.	3.9	60

#	ARTICLE	IF	CITATIONS
19	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. <i>Oncogene</i> , 2010, 29, 305-312.	2.6	83
20	Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. <i>Oncogene</i> , 2010, 29, 3703-3714.	2.6	88
21	Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. <i>Journal of Clinical Investigation</i> , 2010, 120, 840-849.	3.9	134
22	Identification of Early Intestinal Neoplasia Protein Biomarkers Using Laser Capture Microdissection and MALDI MS. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 936-945.	2.5	24
23	Oncogenic Ras and Transforming Growth Factor- β Synergistically Regulate AU-Rich Element-Containing mRNAs during Epithelial to Mesenchymal Transition. <i>Molecular Cancer Research</i> , 2008, 6, 1124-1136.	1.5	38
24	Smad4 Regulates Claudin-1 Expression in a Transforming Growth Factor- β -Independent Manner in Colon Cancer Cells. <i>Cancer Research</i> , 2007, 67, 1571-1579.	0.4	71
25	Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1358-1365.	2.4	74
26	Roles for transforming growth factor- β and transforming growth factor- γ in colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 72-77.	1.0	0
27	Role of Smad proteins in the regulation of NF- κ B by TGF- β in colon cancer cells. <i>Cellular Signalling</i> , 2006, 18, 1041-1050.	1.7	43
28	Smad4-dependent Regulation of Urokinase Plasminogen Activator Secretion and RNA Stability Associated with Invasiveness by Autocrine and Paracrine Transforming Growth Factor- β . <i>Journal of Biological Chemistry</i> , 2006, 281, 33971-33981.	1.6	42
29	Oncogenic Function of a Novel WD-Domain Protein, STRAP, in Human Carcinogenesis. <i>Cancer Research</i> , 2006, 66, 6156-6166.	0.4	77
30	Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1570-1576.	3.2	67
31	Resident Work Hour Limits and Patient Safety. <i>Annals of Surgery</i> , 2005, 241, 847-860.	2.1	111
32	A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. <i>Radiotherapy and Oncology</i> , 2005, 76, 54-58.	0.3	9
33	Smad7 induces tumorigenicity by blocking TGF- β -induced growth inhibition and apoptosis. <i>Experimental Cell Research</i> , 2005, 307, 231-246.	1.2	117
34	A Specific Inhibitor of TGF- β Receptor Kinase, SB-431542, as a Potent Antitumor Agent for Human Cancers. <i>Neoplasia</i> , 2005, 7, 509-521.	2.3	239
35	Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. <i>Journal of Clinical Investigation</i> , 2005, 115, 1765-1776.	3.9	456
36	Enhanced Tumor Formation in Cyclin D1 β -Transforming Growth Factor β 1 Double Transgenic Mice with Characterization by Magnetic Resonance Imaging. <i>Cancer Research</i> , 2004, 64, 1315-1322.	0.4	27

#	ARTICLE	IF	CITATIONS
37	Smad3 has a critical role in TGF- β 2-mediated growth inhibition and apoptosis in colonic epithelial cells. <i>Journal of Surgical Research</i> , 2004, 117, 296-305.	0.8	36
38	Over-expression of cyclin D1 regulates Cdk4 protein synthesis. <i>Cell Proliferation</i> , 2003, 36, 347-360.	2.4	10
39	A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. <i>Nature Biotechnology</i> , 2003, 21, 771-777.	9.4	42
40	Lymphatic Mapping and Sentinel Lymphadenectomy After Preoperative Therapy for Stage II and III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 616-621.	0.7	92
41	Dysregulation of E-cadherin by oncogenic ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. <i>American Journal of Surgery</i> , 2003, 186, 426-430.	0.9	18
42	Regulation of Cyclooxygenase-2 Expression by the Translational Silencer TIA-1. <i>Journal of Experimental Medicine</i> , 2003, 198, 475-481.	4.2	190
43	Vascular Endothelial Growth Factor-Mediated Angiogenesis Inhibition and Postoperative Wound Healing in Rats. <i>Journal of Surgical Research</i> , 2002, 105, 43-47.	0.8	81
44	New Strategies for Colorectal Cancer Prevention and Treatment. <i>World Journal of Surgery</i> , 2002, 26, 762-766.	0.8	26
45	Cyclin D3 Is Essential for Intestinal Epithelial Cell Proliferation. <i>World Journal of Surgery</i> , 2002, 26, 812-818.	0.8	8
46	Induction of Cyclooxygenase-2 and Invasiveness by Transforming Growth Factor- β 1 in Immortalized Mouse Colonocytes Expressing Oncogenic Ras. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 304-309.	0.9	15
47	Transforming Growth Factor- β 1 Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial Cells. <i>Experimental Cell Research</i> , 2001, 266, 239-249.	1.2	74
48	TGF- β and colorectal carcinogenesis. <i>Microscopy Research and Technique</i> , 2001, 52, 450-457.	1.2	42
49	A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. <i>Investigational New Drugs</i> , 2001, 19, 21-27.	1.2	9
50	Oncogenic Ras Represses Transforming Growth Factor- β 2/Smad Signaling by Degrading Tumor Suppressor Smad4. <i>Journal of Biological Chemistry</i> , 2001, 276, 29531-29537.	1.6	106
51	Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. <i>Cancer Research</i> , 2001, 61, 5389-95.	0.4	144
52	Transforming Growth Factor- β 1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA. <i>Journal of Biological Chemistry</i> , 2000, 275, 6628-6635.	1.6	175
53	Oncogenic Ras-mediated Cell Growth Arrest and Apoptosis are Associated with Increased Ubiquitin-dependent Cyclin D1 Degradation. <i>Journal of Biological Chemistry</i> , 2000, 275, 22916-22924.	1.6	70
54	Inhibition of pRb phosphorylation and cell cycle progression by an antenapedia-p16INK4A fusion peptide in pancreatic cancer cells. <i>Cancer Letters</i> , 2000, 159, 151-158.	3.2	37

#	ARTICLE	IF	CITATIONS
55	Presidential address: Evolution. Surgery, 2000, 128, 123-132.	1.0	3
56	Posttranscriptional Regulation of Cyclooxygenase-2 in Rat Intestinal Epithelial Cells. Neoplasia, 2000, 2, 523-530.	2.3	63
57	Coordinate regulation of cyclooxygenase-2 and TGF-1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis, 1999, 20, 185-191.	1.3	72
58	Transformation of intestinal epithelial cells by chronic TGF- β 1 treatment results in downregulation of the type II TGF- β 2 receptor and induction of cyclooxygenase-2. Oncogene, 1999, 18, 855-867.	2.6	58
59	Synergistic Induction of Cyclooxygenase-2 by Transforming Growth Factor- β 1 and Epidermal Growth Factor Inhibits Apoptosis in Epithelial Cells. Neoplasia, 1999, 1, 508-517.	2.3	72
60	¹⁸ F-fluorodeoxyglucose-Positron Emission Tomography in the Management of Patients With Suspected Pancreatic Cancer. Annals of Surgery, 1999, 229, 729.	2.1	170
61	TGF- β 1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene, 1998, 16, 3445-3454.	2.6	77
62	Nuclear translocation of beta-catenin in hereditary and carcinogen- induced intestinal adenomas. Carcinogenesis, 1998, 19, 543-549.	1.3	71
63	Induction of Cyclooxygenase-2 by Activated Ha-ras Oncogene in Rat-1 Fibroblasts and the Role of Mitogen-activated Protein Kinase Pathway. Journal of Biological Chemistry, 1998, 273, 22120-22127.	1.6	161
64	Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research, 1998, 58, 362-6.	0.4	843
65	A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology, 1997, 113, 1883-1891.	0.6	164
66	Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBP β . Nature Medicine, 1997, 3, 1233-1241.	15.2	309
67	Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. Journal of Clinical Investigation, 1997, 99, 2254-2259.	3.9	612
68	Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Research, 1997, 57, 169-75.	0.4	89
69	Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Research, 1997, 57, 1638-43.	0.4	25
70	Short-term caloric restriction augments age-related decreases in gastrin content and release. Mechanisms of Ageing and Development, 1996, 87, 25-33.	2.2	3
71	Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 1996, 111, 1134-1140.	0.6	276
72	Intestinal Cell Cycle Regulation. Annals of Surgery, 1996, 223, 620-628.	2.1	21

#	ARTICLE	IF	CITATIONS
73	Differential regulation by TGF-beta 1 and insulin of insulin-like growth factor binding protein-2 in IEC-6 cells. American Journal of Physiology - Endocrinology and Metabolism, 1995, 268, E1199-E1204.	1.8	6
74	Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene, 1995, 10, 177-84.	2.6	113
75	Transforming growth factor- β 2 inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. American Journal of Surgery, 1994, 167, 14-20.	0.9	40
76	Activation of hepatic proliferation-associated transcription factors by lipopolysaccharide. Surgery, 1994, 116, 367-76; discussion 376-7.	1.0	1
77	Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1. Endocrinology, 1992, 130, 2476-2486.	1.4	13
78	Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis. Molecular Endocrinology, 1992, 6, 1789-1796.	3.7	10
79	The role of endogenous prostaglandins in hormone-stimulated pancreatic exocrine secretion. Gastroenterology, 1992, 102, 272-279.	0.6	4
80	Transforming Growth Factor (TGF)- β 2 Stimulates Hepatic and Proto-oncogenes and Decreases Albumin mRNA. Annals of Surgery, 1992, 216, 300-308.	2.1	11
81	Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells. Biochemical and Biophysical Research Communications, 1992, 185, 577-581.	1.0	18
82	Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. Journal of Cellular Physiology, 1992, 150, 1-7.	2.0	72
83	Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis. Molecular Endocrinology, 1992, 6, 1789-1796.	3.7	8
84	Systemic alterations in ornithine decarboxylase activity caused by colon cancer in mice. Cancer Letters, 1991, 58, 155-158.	3.2	2
85	Differential Effects of Sodium Butyrate and Hexamethylene Bisacetamide on Growth and Secretion of Cultured Human Endocrine Tumor Cells. Archives of Surgery, 1991, 126, 467.	2.3	5
86	Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Research, 1991, 51, 5253-60.	0.4	54
87	Expression of and Response to Growth Regulatory Peptides by Two Human Pancreatic Carcinoma Cell Lines. Pancreas, 1990, 5, 369-380.	0.5	66
88	A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1486-1490.	3.3	372
89	Proglumide inhibits cholecystokinin and meal-stimulated pancreatic secretion and release of pancreatic polypeptide. Surgery, 1990, 108, 553-8.	1.0	0
90	Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 1578-1582.	3.3	308

#	ARTICLE	IF	CITATIONS
91	Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal.. Journal of Clinical Investigation, 1989, 84, 1017-1023.	3.9	231
92	Operative strategies in the management of mediastinal pancreatic pseudocyst. Surgery, 1989, 106, 567-70.	1.0	6
93	Growth factors and intestinal neoplasms. American Journal of Surgery, 1988, 155, 526-536.	0.9	51
94	A High Pressure Liquid Chromatography-Radioimmunoassay Method for Measurement of Cholecystokinin-8 and Cholecystokinin-33/39 in Plasma. Journal of Liquid Chromatography and Related Technologies, 1987, 10, 1431-1438.	0.9	5
95	Role of cholecystokinin in canine pancreatic exocrine response to bombesin stimulation. American Journal of Surgery, 1987, 153, 96-101.	0.9	20
96	Proglumide, A Gastrin Receptor Antagonist, Inhibits Growth of Colon Cancer and Enhances Survival in Mice. Annals of Surgery, 1985, 202, 303-309.	2.1	104